Medicortex Finland Oyj

New Shareholders for Medicortex

Share
Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), announces completion of fundraising campaign. The funds raised will be used to activate research projects in parallel to company’s main product development program.

More than half of the investments in the round came from new investors which means that the company has currently a total of 267 shareholders. Last autumn Medicortex signed a 2 million dollars research grant contract with the US Department of Defense (DoD) to develop a prototype of a rapid test for detection of mild traumatic brain injury or concussion in urine samples.

“While the contract with the DoD supports the main product development activities for the coming year, the grant is bound to the activities presented in the project plan. The funds raised in the share issue enable us to activate parallel initiatives to pave the way for the future products.” says Dr. Adrian Harel, CEO of Medicortex. “Continuous support from many old shareholders together with the public interest and investments by a fair number of new investors indicate that we are on the right path.” Dr. Harel concludes.

Keywords

Contacts

Links

About Medicortex Finland Oyj

Medicortex Finland Oyj
Medicortex Finland Oyj
Itäinen Pitkäkatu 4 B
20520 TURKU

http://www.medicortex.fi

Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an Israeli Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.

Subscribe to releases from Medicortex Finland Oyj

Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oyj

Medicortex Finland Plc signed a 1.4 million dollars research grant contract with the U.S. Department of Defense24.6.2024 11:15:00 EEST | Press release

Medicortex Finland Plc, a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI), announces that the United States Department of Defense (“DoD”) has awarded the company a research grant of about 1.4 million dollars for its project plan to develop a rapid test for detection of mild traumatic brain injury (TBI) and concussion using saliva.

Medicortex Finland Plc appointing new members for the Board of Directors3.5.2024 09:51:16 EEST | Press release

Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI), announces appointment of Nils Grönberg and Ville Ranta-Panula (MSc, MBA) as new members in company’s Board of Directors. Grönberg and Ranta-Panula supplement the team of scientists and clinicians with their diverse expertise in business development and management, among other skills.

Turun kaupunki myönsi Medicortexille TKI-setelin15.6.2023 13:21:40 EEST | Tiedote

Medicortex Finland Oyj, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut 5000 euron arvoisen TKI (tutkimus, kehitys- ja innovaatio-osaaminen) -setelin Turun kaupungilta. Seteli käytetään Turun yliopiston kanssa yhteistyössä tehtävän tutkimushankkeen edistämiseen. Hankkeen tarkoituksena on tutkia sähkömagneettisen säteilyn vaikutusta keskushermostoon koe-eläinmallissa.

Medicortexin kevään 2023 osakeanti päättynyt – yhtiö kiitollinen yleisön mielenkiinnosta30.5.2023 10:45:00 EEST | Tiedote

Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen osakeantikampanjan toisen kierroksen. Kampanjan aikana, joka sijoittui 2023 vuoden ensimmäiselle puolikkaalle, yritys keräsi yli 110 000 euroa. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.

HiddenA line styled icon from Orion Icon Library.Eye